Replies to post #149076 on Biotech Values

[DewDiligence]

AbbVie’s presumptive CEO apparently lied about his academic degrees, although ABT claims the misinformation was an “administrative error”:

http://finance.yahoo.com/news/abbott-misstated-credentials-spinoff-ceo-221416478.html

As an ABT shareholder, I will receive shares of AbbVie on or about 1/1/13; the above revelation might make me more inclined to sell.

(The “new” Abbott after the AbbVie spin-off is a must-own stock, IMO.)